Bessemer Group
ACHN

Bessemer Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Bessemer Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,055
Closed -$8K – 1522
2016
Q1 		$8K Buy
1,055
+429
+69% +$3.14K ﹤0.01% 1179
2015
Q4 		$7K Buy
+626
New +$5.69K ﹤0.01% 1311

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bessemer Group's ACHN Position: Q2 2016 in Review

Bessemer Group sold out of Achillion Pharmaceuticals (ACHN) in Q2 2016, closing a stake of 1,055 shares — an estimated $8K sold.

Bessemer Group first reported a position in ACHN in Q4 2015 and held it in 2 quarters. The position peaked at $8K in Q1 2016. 147 funds tracked by Wall St. Rank hold ACHN as of Q2 2016.

  • Bessemer Group reported no remaining Achillion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Bessemer Group sold 1,055 Achillion Pharmaceuticals shares in Q2 2016, an estimated $8K.
  • Bessemer Group first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Bessemer Group's Achillion Pharmaceuticals position peaked at $8K in Q1 2016.
  • 147 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.